BIIB vs EQBK · P/E 21, rev $9.89B vs P/E 40, rev $215.8M
Biogen Inc (BIIB) versus Equity Bancshares, Inc. (EQBK) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Equity Bancshares, Inc. (EQBK) is a banks - regional company listed on NYSE.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported EQBK revenue for 2026-06-30 was $215.8M. Net income was $43.4M. Revenue was up 99.8% from 2026-03-31 to 2026-06-30. EQBK currently screens at market cap $974.3M and trailing P/E 40.0.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. EQBK currently screens at market cap $974.3M and trailing P/E 40.0.
Not investment advice. Open the BIIB and EQBK stock pages for the full models.
Not investment advice.